Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Sorafenib population pharmacokinetics and skin toxicities in children and adolescents with refractory/relapsed leukemia or solid tumor malignancies.

Inaba H, Panetta JC, Pounds S, Wang L, Li L, Navid F, Federico SM, Eisenmann ED, Vasilyeva A, Wang YD, Shurtleff S, Pui CH, Gruber TA, Ribeiro RC, Rubnitz J, Baker SD.

Clin Cancer Res. 2019 Aug 27. pii: clincanres.0470.2019. doi: 10.1158/1078-0432.CCR-19-0470. [Epub ahead of print]

PMID:
31455680
2.

Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge.

Liu Y, Smith CA, Panetta JC, Yang W, Thompson LE, Counts JP, Molinelli AR, Pei D, Kornegay NM, Crews KR, Swanson H, Cheng C, Karol SE, Evans WE, Inaba H, Pui CH, Jeha S, Relling MV.

J Clin Oncol. 2019 Aug 10;37(23):2051-2061. doi: 10.1200/JCO.18.02439. Epub 2019 Jun 12.

PMID:
31188727
3.

Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models.

Karol SE, Janke LJ, Panetta JC, Ramsey LB, Cai X, Payton MA, Jenkins DA, Evans WE, Relling MV.

PLoS One. 2019 May 6;14(5):e0216328. doi: 10.1371/journal.pone.0216328. eCollection 2019.

4.

Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia.

Browne EK, Zhou Y, Chemaitilly W, Panetta JC, Ness KK, Kaste SC, Cheng C, Relling MV, Pui CH, Inaba H.

Cancer. 2018 Nov 1;124(21):4248-4259. doi: 10.1002/cncr.31736. Epub 2018 Oct 25.

PMID:
30358906
5.

Correction: Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation.

Mohanan E, Panetta JC, Lakshmi KM, Edison ES, Korula A, Fouzia NA, Abraham A, Viswabandya A, Mathews V, George B, Srivastava A, Balasubramanian P.

Bone Marrow Transplant. 2018 Nov;53(11):1490. doi: 10.1038/s41409-018-0276-4.

6.

Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice.

Ganguly S, Panetta JC, Roberts JK, Schuetz EG.

Drug Metab Dispos. 2018 Jul;46(7):1014-1022. doi: 10.1124/dmd.117.078360. Epub 2018 Apr 19.

7.

Bone mineral density in children with acute lymphoblastic leukemia.

Inaba H, Cao X, Han AQ, Panetta JC, Ness KK, Metzger ML, Rubnitz JE, Ribeiro RC, Sandlund JT, Jeha S, Cheng C, Pui CH, Relling MV, Kaste SC.

Cancer. 2018 Mar 1;124(5):1025-1035. doi: 10.1002/cncr.31184. Epub 2017 Dec 19.

8.

Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Mohanan E, Panetta JC, Lakshmi KM, Edison ES, Korula A, Na F, Abraham A, Viswabandya A, George B, Mathews V, Srivastava A, Balasubramanian P.

Clin Pharmacol Ther. 2018 Sep;104(3):575-583. doi: 10.1002/cpt.988. Epub 2018 Jan 17.

9.

Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia.

Budhraja A, Turnis ME, Churchman ML, Kothari A, Yang X, Xu H, Kaminska E, Panetta JC, Finkelstein D, Mullighan CG, Opferman JT.

Clin Cancer Res. 2017 Dec 15;23(24):7558-7568. doi: 10.1158/1078-0432.CCR-17-1231. Epub 2017 Oct 3.

10.

Genetics of pleiotropic effects of dexamethasone.

Ramsey LB, Pounds S, Cheng C, Cao X, Yang W, Smith C, Karol SE, Liu C, Panetta JC, Inaba H, Rubnitz JE, Metzger ML, Ribeiro RC, Sandlund JT, Jeha S, Pui CH, Evans WE, Relling MV.

Pharmacogenet Genomics. 2017 Aug;27(8):294-302. doi: 10.1097/FPC.0000000000000293.

11.

Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation.

Mohanan E, Panetta JC, Lakshmi KM, Edison ES, Korula A, Fouzia NA, Abraham A, Viswabandya A, Mathews V, George B, Srivastava A, Balasubramanian P.

Bone Marrow Transplant. 2017 Jul;52(7):977-983. doi: 10.1038/bmt.2017.79. Epub 2017 May 8. Erratum in: Bone Marrow Transplant. 2018 Nov;53(11):1490.

12.

The effect of body mass index at diagnosis on clinical outcome in children with newly diagnosed acute lymphoblastic leukemia.

Eissa HM, Zhou Y, Panetta JC, Browne EK, Jeha S, Cheng C, Relling MV, Campana D, Pui CH, Inaba H.

Blood Cancer J. 2017 Feb 17;7(2):e531. doi: 10.1038/bcj.2017.11.

13.

Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy.

Liu Y, Fernandez CA, Smith C, Yang W, Cheng C, Panetta JC, Kornegay N, Liu C, Ramsey LB, Karol SE, Janke LJ, Larsen EC, Winick N, Carroll WL, Loh ML, Raetz EA, Hunger SP, Devidas M, Yang JJ, Mullighan CG, Zhang J, Evans WE, Jeha S, Pui CH, Relling MV.

Clin Pharmacol Ther. 2017 Jul;102(1):131-140. doi: 10.1002/cpt.629. Epub 2017 Apr 4.

14.

Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma.

Flerlage JE, Metzger ML, Wu J, Panetta JC.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1217-1223. doi: 10.1007/s00280-016-3180-x. Epub 2016 Nov 11.

15.

Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia.

Varatharajan S, Panetta JC, Abraham A, Karathedath S, Mohanan E, Lakshmi KM, Arthur N, Srivastava VM, Nemani S, George B, Srivastava A, Mathews V, Balasubramanian P.

Cancer Chemother Pharmacol. 2016 Nov;78(5):1051-1058. Epub 2016 Oct 13.

PMID:
27738808
16.

Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate.

Watts CS, Sciasci JN, Pauley JL, Panetta JC, Pei D, Cheng C, Christensen CM, Mikkelsen TS, Pui CH, Jeha S, Relling MV.

J Pediatr Hematol Oncol. 2016 Aug;38(6):449-52. doi: 10.1097/MPH.0000000000000606.

17.

Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice.

Edginton AN, Zimmerman EI, Vasilyeva A, Baker SD, Panetta JC.

Cancer Chemother Pharmacol. 2016 May;77(5):1039-52. doi: 10.1007/s00280-016-3018-6. Epub 2016 Apr 6.

18.

Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant.

Roberts JK, Birg AV, Lin T, Daryani VM, Panetta JC, Broniscer A, Robinson GW, Gajjar AJ, Stewart CF.

Drug Metab Dispos. 2016 Jul;44(7):1116-22. doi: 10.1124/dmd.115.068676. Epub 2016 Apr 6.

19.

MicroRNAs Form Triplexes with Double Stranded DNA at Sequence-Specific Binding Sites; a Eukaryotic Mechanism via which microRNAs Could Directly Alter Gene Expression.

Paugh SW, Coss DR, Bao J, Laudermilk LT, Grace CR, Ferreira AM, Waddell MB, Ridout G, Naeve D, Leuze M, LoCascio PF, Panetta JC, Wilkinson MR, Pui CH, Naeve CW, Uberbacher EC, Bonten EJ, Evans WE.

PLoS Comput Biol. 2016 Feb 4;12(2):e1004744. doi: 10.1371/journal.pcbi.1004744. eCollection 2016 Feb.

20.

Apoptosome activation, an important molecular instigator in 6-mercaptopurine induced Leydig cell death.

Morgan JA, Lynch J, Panetta JC, Wang Y, Frase S, Bao J, Zheng J, Opferman JT, Janke L, Green DM, Chemaitilly W, Schuetz JD.

Sci Rep. 2015 Nov 18;5:16488. doi: 10.1038/srep16488.

21.

Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia.

Churchman ML, Low J, Qu C, Paietta EM, Kasper LH, Chang Y, Payne-Turner D, Althoff MJ, Song G, Chen SC, Ma J, Rusch M, McGoldrick D, Edmonson M, Gupta P, Wang YD, Caufield W, Freeman B, Li L, Panetta JC, Baker S, Yang YL, Roberts KG, McCastlain K, Iacobucci I, Peters JL, Centonze VE, Notta F, Dobson SM, Zandi S, Dick JE, Janke L, Peng J, Kodali K, Pagala V, Min J, Mayasundari A, Williams RT, Willman CL, Rowe J, Luger S, Dickins RA, Guy RK, Chen T, Mullighan CG.

Cancer Cell. 2015 Sep 14;28(3):343-56. doi: 10.1016/j.ccell.2015.07.016. Epub 2015 Aug 27.

22.

Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.

Vasilyeva A, Durmus S, Li L, Wagenaar E, Hu S, Gibson AA, Panetta JC, Mani S, Sparreboom A, Baker SD, Schinkel AH.

Cancer Res. 2015 Jul 1;75(13):2729-36. doi: 10.1158/0008-5472.CAN-15-0280. Epub 2015 May 7.

23.

NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells.

Paugh SW, Bonten EJ, Savic D, Ramsey LB, Thierfelder WE, Gurung P, Malireddi RK, Actis M, Mayasundari A, Min J, Coss DR, Laudermilk LT, Panetta JC, McCorkle JR, Fan Y, Crews KR, Stocco G, Wilkinson MR, Ferreira AM, Cheng C, Yang W, Karol SE, Fernandez CA, Diouf B, Smith C, Hicks JK, Zanut A, Giordanengo A, Crona D, Bianchi JJ, Holmfeldt L, Mullighan CG, den Boer ML, Pieters R, Jeha S, Dunwell TL, Latif F, Bhojwani D, Carroll WL, Pui CH, Myers RM, Guy RK, Kanneganti TD, Relling MV, Evans WE.

Nat Genet. 2015 Jun;47(6):607-14. doi: 10.1038/ng.3283. Epub 2015 May 4.

24.

Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.

Wright KD, Panetta JC, Onar-Thomas A, Reddick WE, Patay Z, Qaddoumi I, Broniscer A, Robinson G, Boop FA, Klimo P Jr, Ward D, Gajjar A, Stewart CF.

Cancer Chemother Pharmacol. 2015 Jan;75(1):27-35. doi: 10.1007/s00280-014-2614-6. Epub 2014 Oct 24.

25.

Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.

Hicks JK, Crews KR, Flynn P, Haidar CE, Daniels CC, Yang W, Panetta JC, Pei D, Scott JR, Molinelli AR, Broeckel U, Bhojwani D, Evans WE, Relling MV.

Pharmacogenomics. 2014 Jun;15(8):1065-78. doi: 10.2217/pgs.14.53.

26.

Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.

Fernandez CA, Stewart E, Panetta JC, Wilkinson MR, Morrison AR, Finkelman FD, Sandlund JT, Pui CH, Jeha S, Relling MV, Campbell PK.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1307-13. doi: 10.1007/s00280-014-2464-2. Epub 2014 Apr 27.

27.

Phase I study of the safety and pharmacokinetics of plerixafor in children undergoing a second allogeneic hematopoietic stem cell transplantation for relapsed or refractory leukemia.

Srinivasan A, Panetta JC, Cross SJ, Pillai A, Triplett BM, Shook DR, Dallas MH, Hartford C, Sunkara A, Kang G, Jacobsen J, Choi J, Leung W.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1224-8. doi: 10.1016/j.bbmt.2014.04.020. Epub 2014 Apr 23.

28.

Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.

Bhojwani D, Sabin ND, Pei D, Yang JJ, Khan RB, Panetta JC, Krull KR, Inaba H, Rubnitz JE, Metzger ML, Howard SC, Ribeiro RC, Cheng C, Reddick WE, Jeha S, Sandlund JT, Evans WE, Pui CH, Relling MV.

J Clin Oncol. 2014 Mar 20;32(9):949-59. doi: 10.1200/JCO.2013.53.0808. Epub 2014 Feb 18.

29.

Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patient with osteosarcoma.

Scott JR, Ward DA, Crews KR, Panetta JC, Navid F.

Pediatr Blood Cancer. 2014 Feb;61(2):373-5. doi: 10.1002/pbc.24741. Epub 2013 Aug 19.

30.

Formalizing an integrative, multidisciplinary cancer therapy discovery workflow.

McGuire MF, Enderling H, Wallace DI, Batra J, Jordan M, Kumar S, Panetta JC, Pasquier E.

Cancer Res. 2013 Oct 15;73(20):6111-7. doi: 10.1158/0008-5472.CAN-13-0310. Epub 2013 Aug 16.

31.

High-throughput asparaginase activity assay in serum of children with leukemia.

Fernandez CA, Cai X, Elozory A, Liu C, Panetta JC, Jeha S, Molinelli AR, Relling MV.

Int J Clin Exp Med. 2013 Aug 1;6(7):478-87. Print 2013.

32.

Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments.

Pauley JL, Panetta JC, Crews KR, Pei D, Cheng C, McCormick J, Howard SC, Sandlund JT, Jeha S, Ribeiro R, Rubnitz J, Pui CH, Evans WE, Relling MV.

Cancer Chemother Pharmacol. 2013 Aug;72(2):369-78. doi: 10.1007/s00280-013-2206-x. Epub 2013 Jun 13. Erratum in: Cancer Chemother Pharmacol. 2013 Dec;72(6):1375.

33.

Mathematical modeling of folate metabolism.

Panetta JC, Paugh SW, Evans WE.

Wiley Interdiscip Rev Syst Biol Med. 2013 Sep-Oct;5(5):603-13. doi: 10.1002/wsbm.1227. Epub 2013 May 22.

34.

Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.

Broniscer A, Baker SD, Wetmore C, Pai Panandiker AS, Huang J, Davidoff AM, Onar-Thomas A, Panetta JC, Chin TK, Merchant TE, Baker JN, Kaste SC, Gajjar A, Stewart CF.

Clin Cancer Res. 2013 Jun 1;19(11):3050-8. doi: 10.1158/1078-0432.CCR-13-0306. Epub 2013 Mar 27.

35.

Genome-wide study of methotrexate clearance replicates SLCO1B1.

Ramsey LB, Panetta JC, Smith C, Yang W, Fan Y, Winick NJ, Martin PL, Cheng C, Devidas M, Pui CH, Evans WE, Hunger SP, Loh M, Relling MV.

Blood. 2013 Feb 7;121(6):898-904. doi: 10.1182/blood-2012-08-452839. Epub 2012 Dec 11.

36.

Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.

Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J, Davidoff AM, Spunt SL, Furman WL, McGregor LM, Hu S, Panetta JC, Turner D, Fofana D, Reddick WE, Leung W, Santana VM.

Clin Cancer Res. 2013 Jan 1;19(1):236-46. doi: 10.1158/1078-0432.CCR-12-1897. Epub 2012 Nov 8. Erratum in: Clin Cancer Res. 2013 Apr 1;19(7):1914.

37.

Population PK/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia.

Rühs H, Becker A, Drescher A, Panetta JC, Pui CH, Relling MV, Jaehde U.

PLoS One. 2012;7(9):e46015. doi: 10.1371/journal.pone.0046015. Epub 2012 Sep 25.

38.

Phase I study of the tolerability and pharmacokinetics of palifermin in children undergoing allogeneic hematopoietic stem cell transplantation.

Srinivasan A, Kasow KA, Cross S, Parrish M, Wang C, Srivastava DK, Cai X, Panetta JC, Leung W.

Biol Blood Marrow Transplant. 2012 Aug;18(8):1309-14. doi: 10.1016/j.bbmt.2012.04.013. Epub 2012 Apr 25.

39.

Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.

Liu C, Kawedia JD, Cheng C, Pei D, Fernandez CA, Cai X, Crews KR, Kaste SC, Panetta JC, Bowman WP, Jeha S, Sandlund JT, Evans WE, Pui CH, Relling MV.

Leukemia. 2012 Nov;26(11):2303-9. doi: 10.1038/leu.2012.102. Epub 2012 Apr 9.

40.

Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.

Christensen AM, Pauley JL, Molinelli AR, Panetta JC, Ward DA, Stewart CF, Hoffman JM, Howard SC, Pui CH, Pappo AS, Relling MV, Crews KR.

Cancer. 2012 Sep 1;118(17):4321-30. doi: 10.1002/cncr.27378. Epub 2012 Jan 17.

41.

Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT.

Balasubramanian P, Desire S, Panetta JC, Lakshmi KM, Mathews V, George B, Viswabandya A, Chandy M, Krishnamoorthy R, Srivastava A.

Bone Marrow Transplant. 2012 Sep;47(9):1178-85. doi: 10.1038/bmt.2011.254. Epub 2012 Jan 9.

PMID:
22231460
42.

Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.

Kawedia JD, Liu C, Pei D, Cheng C, Fernandez CA, Howard SC, Campana D, Panetta JC, Bowman WP, Evans WE, Pui CH, Relling MV.

Blood. 2012 Feb 16;119(7):1658-64. doi: 10.1182/blood-2011-09-381731. Epub 2011 Nov 23.

43.

Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.

Hu S, Niu H, Inaba H, Orwick S, Rose C, Panetta JC, Yang S, Pounds S, Fan Y, Calabrese C, Rehg JE, Campana D, Rubnitz JE, Baker SD.

J Natl Cancer Inst. 2011 Jun 8;103(11):893-905. doi: 10.1093/jnci/djr107. Epub 2011 Apr 12.

44.

Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.

Mikkelsen TS, Sparreboom A, Cheng C, Zhou Y, Boyett JM, Raimondi SC, Panetta JC, Bowman WP, Sandlund JT, Pui CH, Relling MV, Evans WE.

J Clin Oncol. 2011 May 1;29(13):1771-8. doi: 10.1200/JCO.2010.32.5340. Epub 2011 Mar 28.

45.

Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.

Panetta JC, Sparreboom A, Pui CH, Relling MV, Evans WE.

PLoS Comput Biol. 2010 Dec 2;6(12):e1001019. doi: 10.1371/journal.pcbi.1001019.

46.

Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.

Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, Neale G, Howard SC, Evans WE, Pui CH, Relling MV.

Blood. 2011 Feb 24;117(8):2340-7; quiz 2556. doi: 10.1182/blood-2010-10-311969. Epub 2010 Dec 10.

47.

Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.

Zhang F, Tagen M, Throm S, Mallari J, Miller L, Guy RK, Dyer MA, Williams RT, Roussel MF, Nemeth K, Zhu F, Zhang J, Lu M, Panetta JC, Boulos N, Stewart CF.

Drug Metab Dispos. 2011 Jan;39(1):15-21. doi: 10.1124/dmd.110.035915. Epub 2010 Oct 14.

48.

P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice.

Tagen M, Zhuang Y, Zhang F, Harstead KE, Shen J, Schaiquevich P, Fraga CH, Panetta JC, Waters CM, Stewart CF.

Drug Metab Lett. 2010 Dec;4(4):195-201.

49.

Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL.

Vallance K, Liu W, Mandrell BN, Panetta JC, Gattuso JS, Hockenberry M, Zupanec S, Yang L, Yang J, Hinds PS.

Eur J Cancer. 2010 Jul;46(10):1848-55. doi: 10.1016/j.ejca.2010.03.026. Epub 2010 Apr 17.

50.

Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.

McKibbin T, Panetta JC, Fouladi M, Gajjar A, Bai F, Okcu MF, Stewart CF.

Clin Cancer Res. 2010 Feb 1;16(3):1049-57. doi: 10.1158/1078-0432.CCR-09-1997. Epub 2010 Jan 26.

Supplemental Content

Loading ...
Support Center